What is Juno Therapeutics' stock symbol?
Juno Therapeutics trades on the NASDAQ under the ticker symbol "JUNO."
Where is Juno Therapeutics' stock going? Where will Juno Therapeutics' stock price be in 2017?
14 analysts have issued 12-month price targets for Juno Therapeutics' shares. Their forecasts range from $23.00 to $52.00. On average, they expect Juno Therapeutics' stock price to reach $38.43 in the next year.
When will Juno Therapeutics announce their earnings?
Juno Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, February, 27th 2017.
What are analysts saying about Juno Therapeutics stock?
Here are some recent quotes from research analysts about Juno Therapeutics stock:
- Wedbush analysts commented, "We see significant value in JUNO's leading array of engineered T-cell technologies that we believe could allow for a differentiated strategy in B-cell malignancies, despite being behind the competition in the race to market. However, competition from other CAR-T products is likely to limit shareholder upside in the near term." (2/1/2017)
According to Zacks Investment Research, "Juno suffered a huge setback in Jul 2016 with the FDA placing a clinical hold on a phase II study on JCAR015 in patients with relapsed or refractory B cell acute lymphoblastic leukemia. While the hold was lifted a week later and the study resumed under a revised protocol, the company voluntarily placed the study on hold in Nov 2016, and is presently working with the FDA and a Safety Monitoring Board to determine future steps. Moreover, Juno’s shares underperformed the Medical-Biomed/Genetics industry significantly in the past one year. Estimates have been going down lately ahead of the company’s Q4 earnings release. The company has mixed record of earnings surprises in recent quarters. However, Juno continues to progress with its other pipeline candidates and continues to pursue acquisitions and licensing agreements to boost its pipeline." (1/10/2017)
Cowen and Company analysts commented, "At ASH on Monday and JUNO’s investor event, we believe that data from JUNO’s NHL/." (12/5/2016)
Leerink Swann analysts commented, "We’re using a 12% discount rate which we think is appropriate as we use probability-weighted sales estimates for the products and believe the CELG (MP) collaboration, equity investment and ex-US opt-in to CD19 programs lower the risk profile relative to Juno’s peers. We assume the CAR-T market will be split among up to 5 competitors long-term, depending on the indication, including JUNO, KITE, NVS, CLLS, BLUE and others, pending further validation of respective products. Based on the complexity of the technology and manufacturing and the lack of regulatory path for generic versions of CAR-T products as a result of patient-specific manufacturing, we believe that CAR-T product sales are sustainable even after the loss of patent exclusivity." (11/28/2016)
Who owns Juno Therapeutics stock?
Juno Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (10.78%), State Street Corp (3.33%), FMR LLC (1.87%), Temasek Holdings Private Ltd (0.89%), Arrowpoint Asset Management LLC (0.77%) and Brown Advisory Inc. (0.24%). Company insiders that own Juno Therapeutics stock include Anthony B Evnin, Bernard J Cassidy, Douglas K Bratton, Hans Edgar Bishop, Hyam Levitsky, Richard Klausner, Robert Azelby and Steve Harr.
Who sold Juno Therapeutics stock? Who is selling Juno Therapeutics stock?
Juno Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, AQR Capital Management LLC, Clarius Group LLC, Arrowpoint Asset Management LLC, Lumina Fund Management LLC and Baird Financial Group Inc.. Company insiders that have sold Juno Therapeutics stock in the last year include Bernard J Cassidy, Douglas K Bratton, Hans Edgar Bishop, Hyam Levitsky, Richard Klausner, Robert Azelby and Steve Harr.
Who bought Juno Therapeutics stock? Who is buying Juno Therapeutics stock?
Juno Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Brown Advisory Inc., Baillie Gifford & Co., ARK Investment Management LLC, Credit Agricole S A, Guggenheim Capital LLC, Tudor Investment Corp Et Al and Russell Investments Group Ltd..
How do I buy Juno Therapeutics stock?
Shares of Juno Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Juno Therapeutics stock cost?
One share of Juno Therapeutics stock can currently be purchased for approximately $23.09.